Literature DB >> 26975382

What Are the Conditional Survival and Functional Outcomes After Surgical Treatment of 115 Patients With Sacral Chordoma?

Tao Ji1, Wei Guo2, Rongli Yang1, Xiaodong Tang1, Yifei Wang1, Lin Huang1.   

Abstract

BACKGROUND: Conditional survival is a measure of prognosis for patients who have already survived for a specific period of time; however, data on conditional survival after sacrectomy in patients with sacral chordoma are lacking. In addition, because sacral tumors are rare and heterogeneous, classifying them in a way that allows physicians to predict functional outcomes after sacrectomy remains a challenge. QUESTIONS/PURPOSES: (1) What is the overall survival and disease-free survival in patients treated by sacrectomy for chordoma? (2) What is the conditional survival probability and how do prognostic factors change over time in patients undergoing surgical resection for sacral chordoma? (3) What is the local recurrence rate after surgery, how was it treated, and what factors impact on local recurrence? (4) What is the postoperative motor, sensory, bowel, and bladder function by level of resection as determined by using a newly designed scoring method?
METHODS: Between 2003 and 2012, our center treated 122 patients surgically for sacral chordoma. Of those, two died and five were lost before a minimum followup of 1 year was achieved, leaving 115 patients available for analysis in this retrospective study at a mean of 4.9 years (range, 1.3-10.8 years). Basically, single posterior or combined approaches were chosen based on the most cephalad extent of the tumor and resection level was normally at half or one sacral vertebrae above the tumor. The 5-year conditional survival rate was calculated based on Kaplan-Meier survival analysis. The effect of prognostic factors on conditional survival was also explored. A newly designed score method was proposed and adopted in the current study to critically evaluate the functional outcome after resection of the sacrum. Inter- and intraobserver reliability was tested by a preliminary study using kappa statistics and Spearman rank correlation coefficients. Significant interobserver (p < 0.01) and intraobserver agreement (κ > 0.75) were found in nine items between each observer.
RESULTS: The estimated 5-year overall survival rate was 81% (95% confidence interval [CI], 72%-90%) at diagnosis. The 5-year disease-free survival rate was 52% (95% CI, 43%-63%). The 5-year conditional overall survival decreased with each additional year in the first 4 years (81% at diagnosis versus 60% at the fourth year, p < 0.0001) and increased slightly in the fifth year. Patients with adequate surgical margins displayed a higher 5-year survival than those with an inadequate margin (86% [95% CI, 76%-95%] versus 67% [95% CI, 48%-85%], p = 0.01) at diagnosis. Conditional survival estimates for patients who received operations elsewhere were lower than that of newly diagnosed patients treated by us at diagnosis (64% [95% CI, 46%-83%] versus 90% [95% CI, 82%-99%], p = 0.012), but with the numbers we had, we could not detect a difference in conditional survival between those treated elsewhere first compared with those initially treated by us at 5 years. The proposed score system for function evaluation was able to distinguish different levels of resection. The overall functional results for the preservation of bilateral S1, S2, and S3 were 40 ± 8%, 60 ± 12%, and 82 ± 11%, respectively. Patients who had preservation of only one S3 nerve root had more severe incontinence (1.99 ± 0.79 versus 2.60 ± 0.63, p = 0.01) and more sensory loss (1.88 ± 0.82 versus 2.31 ± 0.59, p = 0.02) than those patients with preservation of bilateral S3 nerve roots.
CONCLUSIONS: The 5-year conditional survival for sacral chordoma decreased with each additional year and began to improve after the fourth year. In addition, the effect of the surgical margin and influence of previous surgery on conditional survival were not linear over time. The level of nerve root resections corresponded with the overall function scores according to the proposed scoring method. This information and scoring system should be valuable in discussing outcomes of sacrectomy in patients with chordoma who are considering this operation and serve as the basis for further study. LEVEL OF EVIDENCE: Level III, therapeutic study.

Entities:  

Mesh:

Year:  2017        PMID: 26975382      PMCID: PMC5289164          DOI: 10.1007/s11999-016-4773-8

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  43 in total

1.  Chordoma.

Authors:  D C DAHLIN; C S MACCARTY
Journal:  Cancer       Date:  1952-11       Impact factor: 6.860

2.  Oncologic and functional outcome following sacrectomy for sacral chordoma.

Authors:  Christopher A Hulen; H Thomas Temple; William P Fox; Andrew A Sama; Barth A Green; Frank J Eismont
Journal:  J Bone Joint Surg Am       Date:  2006-07       Impact factor: 5.284

3.  Operative management of sacral chordoma.

Authors:  Bruno Fuchs; Ian D Dickey; Michael J Yaszemski; Carrie Y Inwards; Franklin H Sim
Journal:  J Bone Joint Surg Am       Date:  2005-10       Impact factor: 5.284

4.  Sacral tumor.

Authors:  R Lovett
Journal:  J Kans Med Soc       Date:  1966-11

5.  Chordoma. Thirty-five-year study at Memorial Hospital.

Authors:  N L Higinbotham; R F Phillips; H W Farr; H O Hustu
Journal:  Cancer       Date:  1967-11       Impact factor: 6.860

Review 6.  Current management of sacral chordoma.

Authors:  Daryl R Fourney; Ziya L Gokaslan
Journal:  Neurosurg Focus       Date:  2003-08-15       Impact factor: 4.047

7.  Clinicopathologic study of sacrococcygeal chordoma.

Authors:  T E Kaiser; D J Pritchard; K K Unni
Journal:  Cancer       Date:  1984-06-01       Impact factor: 6.860

8.  Neurological evaluation after radical resection of sacral neoplasms.

Authors:  Y Fujimura; H Maruiwa; T Takahata; Y Toyama
Journal:  Paraplegia       Date:  1994-06

9.  [The surgical management of sacral tumors].

Authors:  Wei Guo; Wan-peng Xu; Rong-Li Yang; Xiao-dong Tang
Journal:  Zhonghua Wai Ke Za Zhi       Date:  2003-11

10.  Conditional survival in ovarian cancer: results from the SEER dataset 1988-2001.

Authors:  Mehee Choi; Clifton D Fuller; Charles R Thomas; Samuel J Wang
Journal:  Gynecol Oncol       Date:  2008-03-07       Impact factor: 5.482

View more
  13 in total

1.  Expert's Comment concerning Grand Rounds case entitled "Cryosurgery in the excision of a giant local recurrent sacral chordoma: a case report and literature review" by V. Pipola et al. (Eur Spine J; https://doi.org/10.1007/s00586-017-5438-3).

Authors:  Sanjay Konakondla; Ziya L Gokaslan
Journal:  Eur Spine J       Date:  2018-11-02       Impact factor: 3.134

Review 2.  Variables affecting functional improvement in chordoma patients admitted to an inpatient rehabilitation facility: A retrospective review.

Authors:  Sasha E Knowlton; Richard Goldstein; Kevin C O'Connor; Joseph Schwab; Francis Hornicek; Ross Zafonte
Journal:  J Spinal Cord Med       Date:  2017-05-02       Impact factor: 1.985

3.  Imaging of spinal chordoma and benign notochordal cell tumor (BNCT) with radiologic pathologic correlation.

Authors:  Mark D Murphey; Matthew J Minn; Alejandro Luiña Contreras; Kelly K Koeller; Robert Y Shih; Carrie Y Inwards; Takehiko Yamaguchi
Journal:  Skeletal Radiol       Date:  2022-09-05       Impact factor: 2.128

4.  Comparison of radiomics machine-learning classifiers and feature selection for differentiation of sacral chordoma and sacral giant cell tumour based on 3D computed tomography features.

Authors:  Ping Yin; Ning Mao; Chao Zhao; Jiangfen Wu; Chao Sun; Lei Chen; Nan Hong
Journal:  Eur Radiol       Date:  2018-10-02       Impact factor: 5.315

5.  Clinical-radiomics nomograms for pre-operative differentiation of sacral chordoma and sacral giant cell tumor based on 3D computed tomography and multiparametric magnetic resonance imaging.

Authors:  Ping Yin; Ning Mao; Sicong Wang; Chao Sun; Nan Hong
Journal:  Br J Radiol       Date:  2019-07-09       Impact factor: 3.039

6.  Managing bowel and bladder impairments in sacral chordoma patients: a case-based approach.

Authors:  Sasha E Knowlton; Cody Andrews; Corey Bindler; Lisa M Ruppert
Journal:  Spinal Cord Ser Cases       Date:  2017-12-12

7.  Total sacrectomy with a combined antero-posterior surgical approach for malignant sacral tumours.

Authors:  Feifei Pu; Zhicai Zhang; Baichuan Wang; Qiang Wu; Jianxiang Liu; Zengwu Shao
Journal:  Int Orthop       Date:  2021-03-25       Impact factor: 3.075

8.  Surgical and Functional Outcomes of En Bloc Resection of Sacral Chordoma: a Retrospective Analysis.

Authors:  Rohit Sharma; Debashish Mukherjee; Amiy Arnav; R Shankaran; Varun Kumar Agarwal
Journal:  Indian J Surg Oncol       Date:  2021-11-19

9.  A case-control study of computer navigation assisted resection of primary sacral chordoma above sacrum 3 level.

Authors:  Yongkun Yang; Yuan Li; Qing Zhang; Xiaohui Niu
Journal:  J Bone Oncol       Date:  2020-06-20       Impact factor: 4.072

10.  Outcomes of Surgery for Sacral Chordoma and Impact of Complications: A Report of 50 Consecutive Patients With Long-Term Follow-Up.

Authors:  Scott L Zuckerman; Sun-Ho Lee; George J Chang; Garrett L Walsh; Reza J Mehran; Ziya L Gokaslan; Ganesh Rao; Claudio E Tatsui; Laurence D Rhines
Journal:  Global Spine J       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.